SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients

WEDNESDAY, Dec. 7, 2022 -- For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-related adverse...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news